Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins
View Patent ↗The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
1. A method of reducing chemotaxis in a subject suffering from lupus nephritis, comprising administering to the subject an isolated antibody or fragment thereof capable of inhibiting chemotaxis in the subject, wherein said antibody or fragment thereof binds a plurality of β-chemokines, wherein said plurality of β-chemokines comprise MCP-1 and at least one other β-chemokine, wherein said antibody or antigen-binding fragment comprises:
a) a heavy chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:29, a CDR2 domain comprising the sequence set forth in SEQ ID NO:30, and a CDR3 domain comprising the sequence set forth in SEQ ID NO: 31; and
b) a light chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:32, a CDR2 domain comprising the sequence set forth in SEQ ID NO:33, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:34
wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
2. The method of claim 1 , wherein the at least one otherβ-chemokine is MCP-2.
3. The method of claim 1 , wherein the antibody is a chimeric antibody.
4. The method of claim 1 , wherein the antibody is a humanized antibody.
5. The method of claim 1 , wherein the fragment is an Fab fragment.
6. The method of claim 1 , wherein the antibody is modified by reducing or eliminating at least one potential glycosylation site.
7. The method of claim 1 , wherein the antibody is modified by conjugation to a carrier selected from polyethylene glycol and albumen.
8. The method of claim 1 , wherein the constant region of the antibody is modified to reduce at least one constant region-mediated biological effector function relative to an unmodified antibody selected from the group of binding to an Fc receptor, opsonization, phagocytosis, and antigen-dependent cellular cytotoxicity.
9. A method of reducing chemotaxis in a subject suffering from lupus nephritis, comprising administering to the subject an isolated antibody capable of inhibiting chemotaxis in the subject, wherein said antibody comprises a heavy chain variable region complementarity determining region (CDR) from an antibody heavy chain variable region set forth in SEQ ID NO:27, wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
10. A method of reducing chemotaxis in a subject suffering from lupus nephritis, comprising administering to the subject an isolated antibody capable of inhibiting chemotaxis in the subject, wherein said antibody comprises a light chain variable region complementarity determining region (CDR) from an antibody light chain variable region as set forth in SEQ ID NO:28, wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
11. A method of reducing chemotaxis a subject suffering from lupus nephritis, comprising administering to the subject an isolated antibody or antigen-binding fragment thereof capable of inhibiting chemotaxis in the subject, wherein said antibody or antigen-binding fragment thereof comprises a variable heavy chain region as set forth in SEQ ID NO:27 and a variable light chain region as set forth in SEQ ID NO:28, wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
12. A method of reducing chemotaxis in a subject suffering from lupus nephritis, comprising administering to the subject an isolated antibody or antigen-binding fragment thereof capable of inhibiting chemotaxis in the subject, wherein said antibody or antigen-binding fragment binds a plurality of β-chemokines, wherein said plurality of β-chemokines comprises MCP-1 and at least one other β-chemokine, wherein said antibody or antigen-binding fragment thereof comprises a variable region complementarity determining region (CDR) from a heavy chain variable region set forth in SEQ ID NO:27, wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
13. The method of claim 12 , wherein the at least one other β-chemokine comprises MCP-2.
14. A method of reducing chemotaxis in a subject suffering from lupus nephritis, comprising administering to the subject an antibody or antigen-binding fragment thereof capable of inhibiting chemotaxis in the subject, wherein said antibody or antigen-binding fragment binds a plurality of β-chemokines, wherein said plurality of β-chemokines comprises MCP-1 and at least one other β-chemokine, wherein said antibody or antigen-binding fragment thereof comprises a variable region complementarity determining region (CDR) from a light chain variable region set forth in SEQ ID NO:28, wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
15. The method of claim 14 , wherein the at least one other p-chemokine comprises MCP-2.
16. A method of reducing chemotaxis in a subject suffering from lupus nephritis, comprising administering to the subject an isolated single-chain antibody antigen-binding fragment capable of inhibiting chemotaxis in the subject, wherein said single-chain antibody antigen-binding fragment specifically binds MCP-1 and at least one other monocyte chemotactic protein, wherein said single-chain antibody antigen-binding fragment comprises a heavy chain variable region complementarity determining region (CDR) from an antibody heavy chain variable region set forth in SEQ ID NO:27 or a light chain variable region complementarity determining region (CDR) from an antibody light chain variable region set forth in SEQ ID NO:28, wherein said single-chain antibody antigen-binding fragment fragment does not have agonistic chemotactic activity for MCP-2, wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1 or MCP-3.
17. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment comprises a variable heavy chain region as set forth in SEQ ID NO: 27 and a variable light chain region as set forth in SEQ ID NO:28.
18. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment binds a plurality of β-chemokines, wherein said plurality of β-chemokines comprises MCP-1 and at least one other β-chemokine, wherein said single-chain antibody antigen-binding fragment comprises:
i. a heavy chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:29, a CDR2 domain comprising the sequence set forth in SEQ ID NO:30, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:31: and
ii. a light chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:32 a CDR2 domain comprising the sequence set forth in SEQ ID NO:33, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:34.
19. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment specifically binds to MCP-1, MCP-2, and MCP-3.
20. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment is a monoclonal antibody.
21. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment is a humanized antibody.
22. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment is selected from the group consisting of an Fab fragment, an Fab′ fragment, an F(ab) 2 fragment, and an Fv fragment.
23. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment is an Fab fragment.
24. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment is conjugated to polyethylene glycol or albumen.
25. The method of claim 16 , wherein the single-chain antibody antigen-binding fragment has a Kd for binding affinity to MCP-1 of 1 pM or less or 0.4 pM to about 0.7 pM.
26. A method of reducing chemotaxis in a subject suffering from lupus nephritis comprising administering to the subject an isolated antibody or fragment thereof capable of blocking chemotaxis, wherein said antibody or antigen-binding fragment comprises:
a) a heavy chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:29, a CDR2 domain comprising the sequence set forth in SEQ ID NO:30, and a CDR3 domain comprising the sequence set forth in SEQ ID NO: 31; and
b) a light chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:32, a CDR2 domain comprising the sequence set forth in SEQ ID NO:33, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:34,
wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.